https://stockhub.co/index.php?action=history&feed=atom&title=CrystalGenomics%2C_Inc.CrystalGenomics, Inc. - Revision history2026-05-25T18:17:21ZRevision history for this page on the wikiMediaWiki 1.43.5https://stockhub.co/index.php?title=CrystalGenomics,_Inc.&diff=67787&oldid=prev95.149.241.133: Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for..."2022-09-22T07:58:59Z<p>Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for..."</p>
<p><b>New page</b></p><div>== Summary<ref>Source: Yahoo Finance.</ref> ==<br />
<br />
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.<br />
<br />
== References and notes == <br />
[[Category:Thesis]]<br />
__INDEX__</div>95.149.241.133